Information Provided By:
Fly News Breaks for January 30, 2020
HOLX
Jan 30, 2020 | 05:28 EDT
Piper Sandler analyst William Quirk raised his price target for Hologic to $61 from $58 following the company's fiscal Q1 results and keeps an Overweight rating on the shares. . Management lowered reported fiscal 2020 guidance following the CynoSure divestiture, and reiterated their confidence in the core business, Quirk tells investors in a post-earnings research note. He believes the divestiture will enable management to "substantially" grow margins and keeps an Overweight rating on Hologic shares.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.